Kennedy Inst Ethics J. 2023;33(3):277-319. doi: 10.1353/ken.2023.a917930.
Abilify MyCite was granted regulatory approval in 2017, becoming the world's first "smart pill" that could digitally track whether patients had taken their medication. The new technology was introduced as one that had gained the support of patients and ethicists alike, and could contribute to solving the widespread and costly problem of patient nonadherence. Here, we offer an in-depth exploration of this narrative, through an examination of the origins and development of Abilify, the drug that would later become MyCite. This history illuminates how an antipsychotic can become a top-selling drug and maintain its blockbuster status for more than a decade. It also provides a detailed case study for how knowledge is constructed within the logic of biomedical capitalism, providing impetus to reexamine claims regarding how MyCite addresses patient nonadherence, engenders patient support, and is ethicist-approved.
阿立哌唑 MyCite 于 2017 年获得监管批准，成为世界上首款可数字化追踪患者是否服药的“智能药丸”。这项新技术被引入，是因为它得到了患者和伦理学家的一致支持，并可能有助于解决普遍且代价高昂的患者不依从性问题。在这里，我们通过考察后来成为 MyCite 的药物阿立哌唑的起源和发展，深入探讨了这一说法。这段历史阐明了一种抗精神病药物如何成为畅销药物，并保持十余年的畅销地位。它还为如何在生物医学资本主义逻辑内构建知识提供了一个详细的案例研究，促使人们重新审视关于 MyCite 如何解决患者不依从性、获得患者支持以及得到伦理学家认可的说法。
